Kornimate/medical-research-clean huggingface dataset:
streamlining radioembolization for small hcc

Conditions: Hepatocellular Carcinoma (HCC)

Summary: in patients who has no sign suggesting high lung shunt fraction (tips, hepatic vein invasion, hepatic vein enhancement on arterial phase, dysmorphic intratumoral vessel, tumor size \< 5cm), radioembolization is performed without maa scan with sir-spheres. this prospective registry will prove that the selection criteria is accurate and streamlining radioembolization is feasible and safe.


Eligibility criteria:
inclusion criteria: * hcc can be diagnosed by aasld guideline * hepatocellular carcinoma 5cm or smaller * dysmorphic intratumoral vessels 3mm or smaller * child-pugh class a * ecog 0 or 1 * the following lab should be met. a. leukocytes ≥ 1,000/µl and ≤ 20,000/µl b. hemoglobin ≥ 6.0 g/dl (transfusion allowed to meet this criterion) c. total bilirubin ≤ 2.0 mg/dl d. platelet ≥ 40,000/µl e. international normalized ratio (inr) ≤ 2.0 for patients not taking anticoagulants f. aspartate transaminase (ast) ≤ 800 iu/l (i.e., ≤ 20x upper normal limit) g. alanine transaminase (alt) ≤ 800 iu/l (i.e., ≤ 20x upper normal limit) h. creatinine ≤ 2.5 mg/dl (if patient is receiving hemodialysis, no upper limit of creatinine) exclusion criteria: * hepatic vein invasion on ct/mri * hepatic vein enhancement on arterial phase of ct/mri * tips * dysmorphic intratumoral vessels \> 3mm * main portal vein invasion * significant copd or interstitial lung disease
frequency of cardiac amyloidosis in the caribbean's. (team amylose)

Conditions: Left Ventricular Hypertrophy

Summary: the frequency of cardiac amyloidosis among patients presenting with a so-called left ventricular hypertrophy remains unknown. this problem is especially relevant in the caribbean's, where an amyloidosis-prone mutation of transthyretin gene might be frequent.

cardiac amyloidosis is a very poorly known disease, in its frequency, its mechanisms, its treatment. this lack of knowledge is a major limitation to the improvement, indispensable, of the care of the patients. in clinical routine, particularly in west indies-guyana, cardiac amyloidosis is a disease poorly identified, whose management remains to be optimized. concordant observations suggest that the frequency of the disease could be significant in the antilles-guyana: aging of the population, high frequency of an amyloidogenic mutation (val122il mutation of the transthyretin gene) found in 4% of the afro-american population, recent identification in martinique by a neurology team of a new founding mutation of the transthyretin gene that may cause the disease. these elements justified the setting up of a multidisciplinary group whose objective is to contribute to the improvement of screening, treatment, and follow-up of patients with cardiac amyloidosis. an identical diagnostic algorithm will be followed in all centers. therapeutic management will be left to the discretion of the health care teams, who will be communicated regularly, the latest management recommendations. a frequency of 30% is expected and will be assessed with a power of 80% and an alpha risk of 0.05. quantitative and qualitative data will be described as usual. differences between groups will be assessed with parametric or non-parametric tests.

Eligibility criteria:
inclusion criteria: * age \> 18 years, * residency in french caribbean regions * access to healthcare coverage, * written informed consent obtained exclusion criteria: * evidence of another cause for left ventricular hypertrophy (uncontrolled severe high blood pressure, untreated severe aortic stenosis, family history of hypertrophic cardiomyopathy) * inability to deliver informed consent, * presence of a known severe disease impending participation in the study

Keywords: cardiac amyloidosis caribbean diagnosis transthyretin
trial of abi-007 in previously treated patients with metastatic melanoma

Conditions: Melanoma; Metastases

Summary: this trial will treat patients previously treated for advanced (metastatic) melanoma (skin cancer) with a new chemotherapeutic medicine. the new chemotherapy will be administered weekly in cycles of three weekly doses followed by one week rest. a minimum of three cycles of therapy will be given to determine the anti-tumor response of the new chemotherapy. patients may continue to stay on therapy a maximum of 9-12 cycles if treatment shows continuing benefit.


Eligibility criteria:
inclusion criteria: * confirmed metastatic melanoma * at least 18 years old * no other active malignancy * hemoglobin at least 9 * platelet count at least 100,000 cells/mm3 * anc at least 1500 cells/mm3 * ast \& alt less than 2.5x upper limit of normal * total bilirubin less than 1.5mg/dl * creatine less than 1.5 mg/dl * alkaline phosphatase less than 2.5x upper limit of normal * life expectancy of at least 12 weeks * ecog performance status of 0-1 * patient must provide informed consent * patient must provide authorization to disclose exclusion criteria: * evidence of active brain metastases * the only evidence of metastasis is lytic or blastic bone metastases * pre-existing peripheral neuropathy of nci toxicity criteria scale of grade greater than 2 * received radiotherapy in last 4wks, except if to a non-target lesion only * clinically significant concurrent illness * investigator's opinion that patient unlikely to complete study * cytotoxic chemotherapeutic agent treatment or investigational drug within previous 4wks * history of allergy/hypersensitivity to study drug * serious medical risk factors determine by the investigator

Keywords: metastatic melanoma
dose-escalation of botulinum toxin in subjects with osteoarthritis of the knee

Conditions: Knee Osteoarthritis

Summary: the purpose of the study is to evaluate the safety and tolerability of the drug product at each dose level.


Eligibility criteria:
inclusion criteria: * osteoarthritis of the knee * fully weight bearing in the index knee with or without the need for assistive/orthopaedic devices * pain score ≥40 mm of the index knee * committing to continue using their assistive/orthopaedic device throughout the study using the same regimen exclusion criteria: * any infection in the index knee or inflammatory skin disease or other inflammatory diseases at the index knee or the anticipated injection site * surgery on the symptomatic knee within the previous 12 months or arthroscopy in the index knee in the past 3 months * any painful orthopaedic disorder of the back or hip which is likely to interfere with the safety or efficacy assessments * a joint disorder other than osteoarthritis in the index knee which could potentially interfere with the safety or efficacy assessments
to evaluate the safety and efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis

Conditions: Relapsing Multiple Sclerosis

Summary: primary objective: to describe the safety of teriflunomide in patients with relapsing forms of multiple sclerosis. secondary objective: to describe the efficacy of teriflunomide in patients with relapsing forms of multiple sclerosis.

the study duration is one year; post treatment safety follow up visit will be conducted 4 weeks after the patient takes the last dose of teriflunomide

Eligibility criteria:
inclusion criteria: * age of patients ≥ 18 years * patients with relapsing form of multiple sclerosis at time of screening visit. * signed written informed consent. exclusion criteria: * patients with hypersensitivity to teriflunomide, leflunomide, or to any excipients in the tablets. * liver function impairment or persisting elevations of serum glutamic pyruvic transaminase (sgpt/alt), serum glutamic oxaloacetic transaminase (sgot/ast), greater than two times the upper limit of normal (uln) during screening visit. * known history of pre-existing acute or chronic liver disease. * patients with significantly (as per investigator's discretion) impaired bone marrow function or significant anemia, leukopenia, or thrombocytopenia. * known history of severe immunodeficiency, acute or severe active infections. * female patients with a positive pregnancy test at screening or women of child-bearing potential who do not agree to use effective methods of contraception throughout the course of the study. * male patients unwilling to use reliable contraception during the course of the study. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
nailfold capillaroscopy evaluation in cushing syndrome patients

Conditions: Cushing Syndrome; Hypercortisolism

Summary: this cross-sectional, single-center study will assess the microvascular function using a nailfold video-capillaroscopy in patients with endogenous cushing syndrome.

endogenous cushing's syndrome (cs) is associated with increased macrovascular diseases and impaired endothelial function. there is no clear data about the effects of hypercortisolism on microcirculation. the primary aim of this study is to evaluate the peripheric microvascular area in patients with cushing's syndrome. the association of microvascular changes with present comorbidities (diabetes, hypertension, etc.) and disease activation will be evaluated. method: cushing syndrome patients admitted to our clinic will be included in this study for the next six months after given informed consent. the following clinical laboratory parameters will be evaluated as cross-sectionally. previous medical history, available laboratory parameters (fasting plasma glucose, hba1c, total cholesterol, triglyceride, hdl, ldl, creatine, ast, alt, complete blood count, acth, dexamethasone suppression tests (1 mg- 2mg), urine free cortisol, fsh, lh, total testosterone, estradiol, igf-1, tsh, free t3, free t4, prolactin), radiologic images (cranial mri and adrenal mri) will be recorded from medical charts. nailfold microcirculation will be evaluated with video-capillaroscopy: it is a non-invasive atraumatic assessment of the morphology and some functional aspects of cutaneous capillaries.

Eligibility criteria:
inclusion criteria: * male and female patients diagnosed as cushing syndrome (cs) caused by acth-producing pituitary adenoma or cortisol producing adrenal adenoma * age between 18 and 70 years exclusion criteria: * chronic glucocorticoid use * cs caused by ectopic acth producing tumors * cs caused by adrenocortical carcinoma * pseudo cs * patients with raynaud phenomenon * patients with collagen tissue disease * patients who use drugs that affect the metabolism of fibrinolysis (such as oral contraceptives) * employees at work at risk of microtrauma (such as gardeners, farmers) * skin diseases with nail fold involvement (such as dermatitis, psoriasis)

Keywords: cushing's syndrome capillaroscopy cushing's disease adrenal adenoma nailfold capillary microvascular circulation
a contribution to the analysis of the phenotypic heterogeneity in crack/cocaine addiction : a case control study

Conditions: Dependence, Cocaine

Summary: the purpose of this study is to assess the phenotypic candidates symptoms, in patients with crack/cocaine addiction, in terms of clinical comorbidities, dimensions of personality, and neuropsychological evaluations apt to be associated with genetic and genotypic characterisations, notably on the polymorphisms of the genes coding or regulating dopaminergic, norepinephrine and serotoninergic systems.

genetic studies show an association between drug addiction and the dopaminergic system and its modulators. nonetheless, results are contradictory, partially due to the heterogeneity of the phenotype addiction. placed on the trafficking route of cocaine, and homogeneously populated, martinique is of particular interest for the study of the vulnerability of the crack/cocaine addiction. in a precedent study, supported by a grant mildt / inserm 2000, on 155 men dependent to crack/cocaine and characterised with three clinical dimensions -sensation seeking, impulsivity and childhood adhd- we found an association between each dimension and polymorphisms of drd2 and drd4 genes.

Eligibility criteria:
inclusion criteria: * diagnosis of cocaine abuse/dependence according to dsm-iv-tr criteria * come from french west indies (3 grandparents are african-caribbean) * sign a written informed consent exclusion criteria: * minor * men with no cocaine abuse/dependence according to dsm-iv-tr criteria for the control: inclusion criteria: * platelets donor * no substance abuse/dependence according to dsm-iv-tr criteria * come from french west indies (3 grandparents are african-caribbean) * sign a written informed consent exclusion criteria: * minor * men refusing a genetic study

Keywords: diagnosis of dependence on cocaine according to dsm-iv-tr criteria
a study for the assessment of the words used by patients and physicians to express asthma symptoms

Conditions: Asthma

Summary: the purpose of the study is to evaluate the concordance of the most frequently used words by the patients and the physicians to express asthma symptoms and the limitations of daily activities caused by asthma.


Eligibility criteria:
inclusion criteria: * diagnosis of persistent asthma treated with inhaled corticosteroid-based maintenance treatment for at least 6 months and followed up by the investigator for at least the same period of time exclusion criteria: * patient with a cardiac disease (congestive heart failure, coronary heart disease) * patient with a respiratory disease other than asthma (copd, sleep apnoea syndrome)

Keywords: asthma language symptoms, limitation of daily activities patients physicians greece
nutrition, growth and development among very preterm infants

Conditions: Low Birth Weight Infant

Summary: the main purpose of this study is to evaluate the effect of increased supply of energy, protein, vitamin a and the long chain polyunsaturated fatty acids docosahexaenoic acid and arachidonic acid on growth, brain maturation and cognitive function.


Eligibility criteria:
inclusion criteria: * birth weight below 1,500 grams * written consent to participate from the parents exclusion criteria: * congenital malformations * clinical syndromes known to affect growth and development * critical illness and short life expectancy * if participants refuse to participate

Keywords: vlbw nutrition vitamin a long-chain unsaturated fatty acids growth cognitive functions very low birth weight infants (birth weight below 1,500 grams).
spot urinary analysis to assess loop diuretic efficiency in stable heart failure

Conditions: Heart Failure

Summary: the primary objective of this study is to assess whether the urinary sodium/creatinine or chloride/creatinine ratio might predict successful downtitration of loop diuretics in patients with stable heart failure without clinical signs of volume overload. in addition, this study will provide information on loop diuretic efficiency and urinary electrolyte composition after intake of diuretics in stable outpatients with heart failure.


Eligibility criteria:
inclusion criteria: * patient has a left ventricular ejection fraction \<40% or has been previously hospitalized with a primary diagnosis of heart failure * patient receives a daily maintenance dose of loop diuretics exclusion criteria: * patient was hospitalized for heart failure \<3 months before study inclusion * the maintenance dose of loop diuretics was changed \<3 months before study inclusion * the maintenance dose of renin-angiotensin-aldosterone system blockers or beta-blocker medication was changed \<3 months before study inclusion * cardiac resynchronization therapy (crt) was initiated \<3 months before study inclusion * at the moment of inclusion, the patient has either one of the following signs of volume overload: lower leg edema +2/4, ascites, lung congestion * patient is not able to measure his/her weight safely and correct at home

Keywords: loop diuretics heart failure natriuresis urinary analysis
an exploratory clinical study to investigate the effect of autostem-oa and allostem-oa in participants with knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: a phase 1 exploratory clinical study to investigate safety, tolerance and efficacy of a single intra-articular injection of autostem-oa or allostem-oa in participants with mild to moderate knee osteoarthritis


Eligibility criteria:
inclusion criteria: 1. informed consent obtained before any study-related activities. study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study. 2. male or female, aged 18 - 60 years (both inclusive) at the time of informed consent. 3. joint pain ≥ 30mm on 100mm vas at screening 4. grade 2-3 kellgren lawrence oa on radiograph with no full-thickness lesion \>1 cm in any dimension by x-ray 5. failure of minimum 2 nonoperative therapies (oral pain medications, physical therapy, corticosteroid injection, or viscosupplementation injection) 6. body mass index (bmi) within the range 18 - 35 kg/m2 (both inclusive) 7. minimum 200 ml of fat (lipoaspirate) available for liposuction at the abdomen and/or thighs as judged by the investigator. 8. agree to donate cells to allostem-oa participants. 9. fulfils eligibility criteria for allogeneic cell- and tissue donors. 10. speaks and reads danish or english exclusion criteria: 1. active tobacco use, or use of other nicotine substitutes 2. active cancer or still in follow-up (5 years) 3. rheumatologic disease 4. avascular disease 5. severe bone deformity 6. previous infection of the knee joint 7. pes anserine bursitis 8. pain attributed to diffuse edema 9. pain attributed to displaced meniscal tear or osteochondritis 10. neurogenic or vascular claudication 11. bleeding disorders 12. chemotherapy 13. radiation therapy to the leg or adipose harvested site 14. knee injections within 3 months of treatment 15. unable to discontinue the following drugs 7 days before injections (prescription pain medication, anticoagulation medicine (including ibuprofen), thrombolytics, antiplatelet medication) 16. use of oral glucocorticoids. 17. female who is pregnant, breast-feeding or intends to become pregnant within 1-year after the treatment, or is of child-bearing potential and not using highly effective contraceptive method. 18. known chronic disease associated with metabolism malfunction or poor healing. 19. allergy towards necessary anaesthesia 20. varus/valgus malalignment \>5° 21. isolated patellofemoral arthrosis
high-risk prostate cancer radiation versus surgery

Conditions: Prostate Cancer; Prostate Adenocarcinoma

Summary: prospective cohort study comparing robot-assisted radical prostatectomy and external beam radiotherapy combined with androgen deprivation therapy for high-risk non-metastatic prostate cancer in terms of health-related quality of life, functional outcomes, cost-effectiveness, progression-free survival and distant metastasis-free survival.

detailed description: robot assisted radical prostatectomy (rarp) and external beam radiotherapy (ebrt) combined with androgen deprivation therapy (adt) are widely used treatment modalities for high-risk non-metastatic prostate cancer (hr-pca). both treatments are associated with adverse effects and can have a great impact on health-related quality of life (hrqol). to date there is no consensus on which of both is the optimal treatment for men with hr-pca, as it is unclear which treatment is superior in terms of hrqol, cost-effectiveness, progression-free survival (pfs) and distant metastases-free survival (dmfs). this is reflected in substantial variation between individual hospitals in the utilization of both treatment options that is not explained by patient- and tumor characteristics or patient preferences. in the recover study we aim to address this knowledge gap. the insights gained can be used to tailor recommendations in (national) guidelines and in shared decision-making tools. this allows healthcare professionals to better inform their patients and allows patients to make well-informed choices.

Eligibility criteria:
inclusion criteria: * histologically confirmed de novo non-metastatic high-risk prostate cancer. * ct3a-bn0m0, according to the 8th edition of the tumour, node, metastasis (tnm) classification, with the exception that clinical t-stage will be based on digital rectal examination and magnetic resonance imaging (the highest stage will be used) and/or * international society of urological pathology (isup) grade ≥4 and/or * prostate-specific antigen (psa) value at diagnosis greater than 20 ng/ml * fit for treatment with either rarp or ebrt and adt (who performance status 0-1) * living in the netherlands * able to read and understand the dutch language exclusion criteria: * histological types other than adenocarcinoma * diagnosis and/or treatment in a hospital abroad * treatment with androgen receptor targeted agents (arta) as part of the initial treatment plan

Keywords: radical prostatectomy radiotherapy health-related quality of life functional outcomes progression-free survival distant metastases-free survival cost-effectiveness
use of n-butyl cyanoacrylate in transarterial emergency embolization

Conditions: Haemostasis Embolisation

Summary: nbca is a synthetic biodegradable cyanoacrylate basis glue, modified by the addition of a monomer with adhesive, hemostatic, and antiseptic properties. its use requires a steep learning curve to control emulsification of the nbca/lipiodol mixture, and injection, to avoid non-target embolization. the aim of this retrospective monocentric study was to evaluate safety and efficacy of use of nbca as embolic agent in emergency setting.


Eligibility criteria:
inclusion criteria: * all patients referred to our hospital and treated by tae with nbca, based on clinical decisions in emergency and ct scan. exclusion criteria: * patients lost for follow-up, patients without preoperative ct.

Keywords: emergency hemostatic agent nbca bleeding trans-arterial embolisation
real world data in lymphoma and survival in adults

Conditions: Diffuse Large B Lymphoma (DLBCL); Follicular Lymphoma (FL); Mantle Cell Lymphoma (MCL); Marginal Zone Lymphoma (MZL); T-cell Lymphoma (T-NHL); Hodgkin's Lymphoma (HL); Burkitt Lymphoma (BL))

Summary: realysa cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. realysa is a platform perfectly set up to * study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (qol)... * document treatment effectiveness in real life and observance * address socio-economical questions


Eligibility criteria:
inclusion criteria: * signature of the consent form for participation in the realysa cohort * aged over 18 at the time of inclusion * diagnosed with lymphoma in the last 6 months (180 days) * lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large b-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, t-cell lymphoma, hodgkin's lymphoma, burkitt lymphoma exclusion criteria: * anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination) * documented hiv infection * any other lymphoma subtype not included in the list in appendix 1. of note, are excluded: * chronic lymphocytic leukemia/small lymphocytic lymphoma * hairy cell leukemia and variant * lymphoplasmacytic lymphoma * waldenström macroglobulinemia * primary dlbcl of the central nervous system (cns) * t-cell large granular lymphocytic leukemia * chronic lymphoproliferative disorder of nk cells * mycosis fungoides * sézary syndrome * primary cutaneous t cell lymphomas (mainly diagnosed and treated by dermatologists) * post-transplant lymphoproliferative disorders (ptld)

Keywords: lymphoma real life cohort epidemiology pro